Eighteen living related liver transplants for Wilson's disease: a single-center
- PMID: 15561206
- DOI: 10.1016/j.transproceed.2004.06.029
Eighteen living related liver transplants for Wilson's disease: a single-center
Abstract
The aim of this study was to review our experience with living related liver transplantation (LRLT) for Wilson's disease. From January 2001 to July 2003 LRLT were performed in 18 patients with Wilson's disease, seven of whom had neurologic complications. The mean age of the patients was 13.5 +/- 2.3 years (range 6 to 20). Before transplantation all recipients displayed low serum ceruloplasmin levels (mean value = 118.4 +/- 32.6 mg/L). The serum ceruloplasmin levels increased to an average of 236.8 +/- 38.5 mg/L after LRLT at the latest evaluation, which ranged between 2 and 32 months after transplantation. A marked reduction in urinary copper excretion was observed in all recipients after transplantation. All recipients are alive and remain well. None have developed signs of recurrent Wilson's disease after a mean follow-up of 18.2 +/- 9.4 months (range 2 to 32 months). The donors were 17 mothers and one father of mean age 34.0 +/- 3.0 years (range 30 to 45 years). The serum ceruloplasmin levels were within normal limits in all donors (mean 226 +/- 27.8 mg/L). Two donors had biliary leakage and percutaneous drainage Grafts included four right lobes without the hepatic middle vein and 14 left lobe grafts with the middle vein. LRLT is a curative procedure for Wilson's disease presenting with fulminant hepatic failure and the others with end-stage hepatic insufficiency. After liver transplantation, the serum ceruloplasmin level increases to the normal range, urinary copper excretion decreases, and neurological manifestations improve to various extents.
Similar articles
-
Liver transplantation for Wilson's disease.Transplant Proc. 2008 Jan-Feb;40(1):228-30. doi: 10.1016/j.transproceed.2007.11.007. Transplant Proc. 2008. PMID: 18261593
-
Copper metabolism after living related liver transplantation for Wilson's disease.World J Gastroenterol. 2003 Dec;9(12):2836-8. doi: 10.3748/wjg.v9.i12.2836. World J Gastroenterol. 2003. PMID: 14669346 Free PMC article.
-
Living-related liver transplantation for Wilson's disease.Clin Transplant. 2005 Aug;19(4):483-6. doi: 10.1111/j.1399-0012.2005.00371.x. Clin Transplant. 2005. PMID: 16008592
-
Wilson's disease: a new gene and an animal model for an old disease.J Investig Med. 1995 Aug;43(4):323-36. J Investig Med. 1995. PMID: 7552582 Review.
-
[Wilson's disease].Acta Med Croatica. 2003;57(3):227-35. Acta Med Croatica. 2003. PMID: 14582469 Review. Croatian.
Cited by
-
Monitoring of Copper in Wilson Disease.Diagnostics (Basel). 2023 May 23;13(11):1830. doi: 10.3390/diagnostics13111830. Diagnostics (Basel). 2023. PMID: 37296680 Free PMC article. Review.
-
Liver transplantation in Wilson disease: a single-center experience.Orphanet J Rare Dis. 2025 Jun 10;20(1):292. doi: 10.1186/s13023-025-03827-9. Orphanet J Rare Dis. 2025. PMID: 40495164 Free PMC article.
-
Liver transplantation for Wilson disease.World J Hepatol. 2012 Jan 27;4(1):5-10. doi: 10.4254/wjh.v4.i1.5. World J Hepatol. 2012. PMID: 22312450 Free PMC article.
-
Liver transplantation as a treatment for Wilson's disease with neurological presentation: a systematic literature review.Acta Neurol Belg. 2022 Apr;122(2):505-518. doi: 10.1007/s13760-022-01872-w. Epub 2022 Jan 26. Acta Neurol Belg. 2022. PMID: 35080708 Free PMC article.
-
Zinc monotherapy and a low-copper diet are beneficial in patients with Wilson disease after liver transplantation.CNS Neurosci Ther. 2013 Nov;19(11):905-7. doi: 10.1111/cns.12167. Epub 2013 Oct 14. CNS Neurosci Ther. 2013. PMID: 24119323 Free PMC article. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical